Insider Selling: Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells 3,000 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock in a transaction on Monday, March 24th. The shares were sold at an average price of $45.63, for a total value of $136,890.00. Following the completion of the transaction, the chief executive officer now owns 37,916 shares of the company’s stock, valued at approximately $1,730,107.08. This trade represents a 7.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Thomas David Hull III also recently made the following trade(s):

• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The stock was sold at an average price of $48.53, for a total value of $10,336.89.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The stock was sold at an average price of $60.08, for a total transaction of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total transaction of $126,020.00.

Kewaunee Scientific Price Performance

Shares of NASDAQ KEQU opened at $44.96 on Tuesday. The stock’s 50-day simple moving average is $57.26 and its two-hundred day simple moving average is $47.64. Kewaunee Scientific Co. has a twelve month low of $30.82 and a twelve month high of $71.33. The firm has a market capitalization of $128.36 million, a P/E ratio of 7.13 and a beta of 0.71. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45.

Kewaunee Scientific (NASDAQ:KEQU) last posted its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. Kewaunee Scientific had a net margin of 9.39% and a return on equity of 25.83%. The company had revenue of $67.17 million for the quarter.

Institutional Trading of Kewaunee Scientific

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in Kewaunee Scientific by 2,605.9% during the fourth quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock valued at $28,000 after purchasing an additional 443 shares in the last quarter. IFP Advisors Inc bought a new position in shares of Kewaunee Scientific during the 4th quarter valued at about $36,000. JPMorgan Chase & Co. raised its holdings in shares of Kewaunee Scientific by 18,000.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock valued at $30,000 after buying an additional 900 shares in the last quarter. Morgan Dempsey Capital Management LLC bought a new stake in Kewaunee Scientific in the 4th quarter worth approximately $106,000. Finally, Barclays PLC purchased a new stake in Kewaunee Scientific in the third quarter worth approximately $121,000. 32.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research report on Friday, March 14th.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.